Company: SCYX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001140361-25-016641
Chunk: 36

Company: SCYNEXIS INC
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 36
---
 on the achievement of corporate goals (weighted 80%) which were achieved at 93% of target and individual performance (weighted 20%) which were achieved at 103% for each, resulting in annual performance bonuses of $171,912 and $169,146 for Mr. Macleod and Mr. Sukenick, respectively. Equity-Based Incentive Awards Our long-term, equity-based incentive awards are designed to align the interests of our executive officers and our other employees, non-employee directors, and consultants with the interests of our stockholders. Because vesting is generally subject to continued service over a period of several years following the date of grant, our equity-based incentives also serve as a retention device for executive officers, employees and other service providers. We generally provide initial equity-based incentive awards in connection with the commencement of employment of our executive officers as an inducement to commencement of employment, and we generally grant annual equity-based incentive awards to our executive officers shortly following the end of each year, each of which are subject to vesting over a period of multiple years in order to facilitate retention. In January 2024, as part of its annual performance compensation review, the Compensation Committee (a) awarded the following restricted stock units to our named executive officers to acquire the following numbers of shares: Dr. Angulo, 290,590 shares; Mr. Macleod, 143,675 shares; and Mr. Sukenick, 143,675 shares, and (b) awarded options to our named executive officers to purchase the following number of shares: Dr. Angulo, 431,030 shares; Mr. Macleod, 215,515 shares; and Mr. Sukenick, 215,515 shares.

24

TABLE OF CONTENTS

The shares subject to the restricted stock units described above vest over three years in equal annual installments. The stock options described above vest in equal monthly installments for 48 months as measured from the date of grant, subject to continued employment through the respective vesting date and allows for the purchase shares of our common stock at a price equal to $1.86, the fair market value of our common stock on January 26, 2024, the date of grant. Other Compensation and Benefits All of our named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, vision and life plans, and our 401(k) plan, in each case on the same basis as all of our other employees. We pay the